PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy.

Acta Pharmacologica Sinica
Qian LiPei-Qing Liu

Abstract

High-mobility group box 1 (HMGB1) exhibits various functions according to its subcellular location, which is finely conditioned by diverse post-translational modifications, such as acetylation. The nuclear HMGB1 may prevent from cardiac hypertrophy, whereas its exogenous protein is proven to induce hypertrophic response. This present study sought to investigate the regulatory relationships between poly(ADP-ribose) polymerase 1 (PARP1) and HMGB1 in the process of pathological myocardial hypertrophy. Primary-cultured neonatal rat cardiomyocytes (NRCMs) were respectively incubated with three cardiac hypertrophic stimulants, including angiotensin II (Ang II), phenylephrine (PE), and isoproterenol (ISO), and cell surface area and the mRNA expression of hypertrophic biomarkers were measured. the catalytic activity of PARP1 was remarkably enhanced, meanwhile HMGB1 excluded from the nucleus. PARP1 overexpression by infecting with adenovirus PARP1 (Ad-PARP1) promoted the nuclear export of HMGB1, facilitated its secretion outside the cell, aggravated cardiomyocyte hypertrophy, which could be alleviated by HMGB1 overexpression. PE treatment led to the similar results, while that effect was widely depressed by PARP1 silencing or its specif...Continue Reading

References

Jun 1, 1995·British Heart Journal·P E GlennonP A Poole-Wilson
Apr 7, 2004·Circulation·Norbert FreyJoseph A Hill
Apr 25, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Jyothish B PillaiMahesh P Gupta
Sep 25, 2007·Nature Cell Biology·Masayuki KanaiKenji Fukasawa
Feb 27, 2008·Molecular and Cellular Biology·Opeyemi A OlabisiChi-Wing Chow
Mar 14, 2009·Biochemical and Biophysical Research Communications·Jun-ichi SakamakiAkiyoshi Fukamizu
Sep 14, 2010·Molecular Cell·Raga Krishnakumar, W Lee Kraus
Nov 26, 2010·Molecular Cell·Peter LönnAristidis Moustakas
Mar 5, 2013·International Journal of Cardiology·Jørgen GravningHåvard Attramadal
Oct 9, 2013·Proceedings of the National Academy of Sciences of the United States of America·Charis PutinskiLynn A Megeney
Apr 11, 2014·Hormones & Cancer·Madhuwanti SrinivasanGnanasekar Munirathinam
Jul 6, 2014·Proceedings of the National Academy of Sciences of the United States of America·Shaida A AndrabiTed M Dawson
Nov 14, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Zhiyong YangChunyou Wang
Jan 28, 2015·British Journal of Pharmacology·Xiao-Jun FengPei-Qing Liu
Dec 10, 2015·Journal of Cellular and Molecular Medicine·Lei ZhangJunbo Ge
Mar 27, 2016·Translational Research : the Journal of Laboratory and Clinical Medicine·Jing LuPeiqing Liu
Apr 21, 2016·Journal of Pharmacological Sciences·Peiye ShenPeiqing Liu
Apr 29, 2016·Journal of Cardiovascular Pharmacology·Xiaoying ZhangPeiqing Liu
Jul 6, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Emilie VenereauMarco E Bianchi
Jul 18, 2016·Experimental Cell Research·Zhongbao YuePeiqing Liu

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme linked immunosorbent assay
PCR
co-immunoprecipitation
transfection
ELISA
PARylation
co-IP
transfecting

Software Mentioned

Image Analysis
Image J

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.